Sep 23 |
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
Sep 6 |
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
|
Sep 5 |
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
|
Sep 4 |
Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
|
Sep 4 |
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
|
Sep 4 |
High-dose Spinraza meets study goal; Top Dyne executives exit
|
Sep 3 |
Dyne stock tumbles 31% amid drug updates, management changes
|
Sep 3 |
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
|
Sep 3 |
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
|
Sep 3 |
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
|